Eli Lilly boosts 2024 revenue guidance by $3 billion on Mounjaro, Zepbound sales

Taking stock of the drug industry, from the lab to the medicine chest

August 8, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Eli Lilly boosts 2024 revenue guidance by $3 billion on Mounjaro, Zepbound sales An earnings report shows the rapid growth of Lilly's GLP-1 business, even as the company struggled with shortages throughout the first half of the year. By Elaine Chen STAT+ | A U.K. trade group scolds Novo again — this time for remarks made by its CEO The remarks made by Novo chief executive Lars Jorgensen were misleading and failed to mention potential risks, the trade group determined. By Ed Silverman STAT+ | Vertex, U.K. reach deal to provide CRISPR-based medicine to thalassemia patients in England Patients in the country with beta thalassemia will now be able to receive the one-time treatment, called Casgevy. By Andrew Joseph Anna Yeo/STAT Watch: How drug patents pave the way to profit Part 3 of "Behind the Counter," a STAT video explainer series exploring the complex relationship of drug patents and high prescription drug prices. By Anna Yeo STAT+ | AI drug developers Recursion, Exscientia to merge Recursion shareholders will own approximately 74% of the combined company and Exscientia shareholders will own approximately 26%. By Allison DeAngelis FDA approves Purdue Pharma's controversial new overdose-reversal medication Amid the overdose epidemic, Purdue is viewed as a villain. The company said it plans to sell Zurnai, its medication to reverse opioid overdoses, at cost. By Lev Facher

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser